Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at Medical University of Vienna. The agreement, co-signed by Phoenestra GmbH, covers the preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU, the company's lead biologic candidate. For a sector still contending with high failure rates and lengthy development timelines, the deal signals a concrete step toward moving a preclinical asset into human testing and underscores the growing role of European academic medical centers in early-stage life sciences translation.
LK-ICU consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells. Preclinical studies indicate that the therapy almost completely preserves both diaphragm muscle fiber size and function, which are normally compromised by the use of mechanical ventilation. This matters because ventilator-induced diaphragm dysfunction is a major contributor to ICU-acquired weakness, a condition that can prolong weaning from mechanical ventilation and is estimated to affect the quality of life of hundreds of thousands of patients each year in the United States and Europe. By targeting the muscle damage at its source, LK-ICU could address an unmet need that extends far beyond the ICU stay itself.
According to the announcement, Leksum plans to start efforts under the agreement upon closing its Series A financing. The planning phase is expected to last several months, and the company intends to use European clinical data to support its U.S. regulatory path. That transatlantic strategy is notable for an early-stage company: it suggests a desire to generate robust human data in a well-regarded academic setting while laying groundwork for eventual FDA interactions. The involvement of the Medical University of Vienna adds clinical and scientific credibility, and the co-signature of Phoenestra GmbH points to a collaborative, multi-party effort rather than a single-sponsor endeavor.
The agreement also highlights the broader pipeline ambitions of Leksum. The company is developing advanced biologic therapies to address acquired muscle myopathies, not only in critical care but also in skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss associated with the use of weight-loss drugs like GLP-1s. If LK-ICU succeeds in preserving diaphragm function, the underlying extracellular vesicle platform could have implications for a range of muscle-wasting conditions, making this preparatory work a potentially pivotal test of the company's scientific approach. The full announcement, including downloadable images and bios, is available click here.
For patients and clinicians, the significance lies in the possibility of reducing the burden of ICU-acquired weakness. Prolonged mechanical ventilation is associated with higher morbidity, longer hospital stays, and diminished long-term recovery. A therapy that protects the diaphragm could shorten weaning times and improve outcomes, though the path from agreement to approved treatment remains long and uncertain. The coming months of planning, followed by first-in-human trials, will be closely watched as an early indicator of whether this vesicle-based strategy can deliver on its preclinical promise.
